2 Citations (Scopus)


OBJECTIVE: S100B is a glial cell protein with bimodal function. In low concentrations, it exerts neurotrophic effects, but higher levels reflect neuronal distress. Recent research suggests that this molecule may be a biomarker of response to electroconvulsive therapy (ECT). We examined the effect of ECT on serum S100B and its utility as 1) a biomarker of a depressive state and 2) a predictor of ECT response. We also wanted to ensure that ECT does not cause a marked serum S100B elevation, indicating neural distress.

METHODS: We measured serum S100B in 22 in-patients treated with ECT due to depression. Depression severity was assessed using 17-item Hamilton Rating Scale for Depression (HAMD-17). The data were collected before an ECT series, within 1 week after the series (post-ECT), and at a 6-month follow-up. Changes in serum S100B and clinical outcomes were tested using a linear mixed model. A relationship between serum S100B and the clinical outcomes was examined using Spearman's and partial correlation.

RESULTS: Serum S100B did not change significantly immediately after an ECT series or 6 months later. The post-ECT serum S100B change was not associated with the clinical effect (rho = 0.14, n = 22, p = 0.54). The baseline serum S100B did not predict the clinical effect when controlling for age (r = 0.02, n = 22, df = 19, p = 0.92).

CONCLUSION: The study neither supports serum S100B as a state marker of depression nor a predictor of ECT response. No evidence for ECT-related neural distress was found.

Original languageEnglish
JournalActa Neuropsychiatrica
Issue number5
Pages (from-to)269-275
Number of pages7
Publication statusPublished - Oct 2022


  • Biomarkers
  • Depression/therapy
  • Electroconvulsive Therapy
  • Humans
  • S100 Calcium Binding Protein beta Subunit
  • Treatment Outcome


Dive into the research topics of 'Serum S100B protein after electroconvulsive therapy in patients with depression'. Together they form a unique fingerprint.

Cite this